Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer

International Journal of Biological Markers

Volumn 15, Issue 1, 2000, Pages 79-83

  Harbeck, N ^a   Alt, U ^a   Berger, U ^b   Kates, R ^b   Kruger A ^a   Thomssen, C ^c   Janicke F ^c   Graeff, H ^a   Schmitt, M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Breast cancer; Cathepsin D B L; Invasion; PAI 2; Prognosis; uPA

Indexed keywords

ANTINEOPLASTIC AGENT; CATHEPSIN B; CATHEPSIN D; CATHEPSIN L; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ADULT; AGED; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CONFERENCE PAPER; CYTOSOL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PROGNOSIS; RELAPSE;

EID: 0034035376     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080001500115     Document Type: Conference Paper

References (30)

1. Duffy MJ, Reilley D, O'Sullivan C, O'Higgins N, Fennelly JN, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990; 50: 6827-9.
2. Jänicke F, Schmitt M, Pache L, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong, independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993; 24: 195-208.
3. Grøhndahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53: 2513-21.
4. Foekens JA, Schmitt M, van Putten WLJ, et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994; 12: 1648-58.
5. Fernö M, Bendahl PO, Borg A, et al. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 1996; 32A: 793-801.
6. Kim SJ, Shiba E, Kobayashi T, et al. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhib-itor type 1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on a multicenter basis. Clin Cancer Res 1998; 4: 177-82.
7. Harbeck N, Thomssen C, Berger U, et al. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treat 1999; 54: 147-57.
8. Bouchet C, Hacène K, Martin JP, et al. Dissemination risk index based on plasminogen activator system components in primary breast cancer. J Clin Oncol 1999; 17: 3048-57.
9. Thorpe SM, Rochefort H, Garcia M, et al. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 11989; 49: 6008-14.
10. Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL. Cathepsin D and prognosis in breast cancer. New Engl J Med 1990; 322: 297-302.
11. Fernö M, Baldetorp B, Borg Å, et al, for the South Sweden Breast Cancer Group. Cathepsin D, both a prognos-tic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. Eur J Cancer 1994; 30A: 2042-8.
12. Ferrandina G, Scambia G, Bardelli F, Benedetti Panici P, Manusco S, Messori A. Relationship between cathepsin D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer 1997; 76: 661-6.
13. Foekens J, Look MP, Bolt-de-Vries J, Meijer-van Gelder ME, van Putten WLJ, Klijn JGM. Cathepsin D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 1999; 79: 300-7.
14. Kos J, Lah TT. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). Oncology reports 1998; 5: 1349-61.
15. Thomssen C, Schmitt M, Goretzki L, et al. Prognostic values of the cysteine protease cathepsin B and L in human breast cancer. Clin Cancer Res 1995; 1: 741-6.
16. Foekens J, Kos J, Peters HA, et al. Prognostic signifi-cance of cathepsins B and L in primary human breast cancer. J Clin Oncol 1998; 16: 1013-21.
17. Twining SS. Regulation of proteolytic activity in tissues. Crit Rev Biochem Mol Biol 1994; 29: 315-83.
18. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1-22.
19. Chapman HA, Riese RJ, Shi GP. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 1997; 59: 63-88.
20. Murphy G, Knauper V. Relating matrix metalloprotein-ase structure to function: why the "hemopexin" domain? Matrix Biol 1997; 15: 511-8.
21. Kute TE, Grøhndahl-Hansen J, Shao SM, Long R, Russell G, Brünner N. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 1998; 47: 9-16.
22. van der Stappen JW, Williams AC, Maciewicz RA, Paraskeva C. Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int J Cancer 1996; 67: 547-54.
23. Kobayashi H, Schmitt M, Goretzki L, et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J Biol Chem 1991; 266: 5147-52.
24. Delia Porta P, Soeltl R, Krell HW, et al. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo. Anticancer Res 1999; 9: 3809-16.
25. Noel A, Gilles C, Bajou K, et al. Emerging roles for proteinases in cancer. Invasion Metastasis 1997; 17: 221-39.
26. Schmitt M, Jänicke F, Graeff H. Tumor-associated proteases. Fibrinolysis 1992; 6: 3-26.
27. Schmitt M, Thomssen C, Ulm K, et al. Time-varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1, and steroid hormone receptor status in primary breast cancer. Br J Cancer 1997; 76: 306-11.
28. Harbeck N, Dettmar P, Thomssen C, et al. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: six-year median follow-up. Br J Cancer 1999; 80: 419-26.
29. Jänicke F, Thomssen C, Pache L, Schmitt M, Graeff H. Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. In: Schmitt M, Graeff H, Jänicke F, eds. Prospects in diagnosis and treatment of cancer. Amsterdam: Elsevier Science Publishers 1994; 207-18.
30. Thomssen C, Oppelt P, Jänicke F, et al. Identification of low-risk node-negative breast cancer patients by tumor-biological factors PAI-1 and cathepsin L. Anticancer Res 1998; 18: 2173-80.